Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M324Revenue $M65.0Net Margin (%)17.5Z-Score12.9
Enterprise Value $M246EPS $0.5Operating Margin %18.1F-Score0
P/E(ttm))25.9Cash Flow Per Share $0Pre-tax Margin (%)17.3Higher ROA y-yN
Price/Book2.810-y EBITDA Growth Rate %0Quick Ratio6.2Cash flow > EarningsN
Price/Sales3.15-y EBITDA Growth Rate %0Current Ratio7.0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-40.2ROA % (ttm)8.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)9.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M21.6ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with ENZY

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ENZYJohn Paulson 2014-03-31 Sold Out -0.23%$21.52 - $29.5
($26.63)
$ 14.84-44%Sold Out0
ENZYJohn Paulson 2013-12-31 Buy 0.23%$16.555 - $33.44
($23.85)
$ 14.84-38%New holding, 1733030 sh.1,733,030
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ENZY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ENZY John Paulson 2014-03-314,271,23019.810.46New Buy
ENZY John Paulson 2014-03-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ENZY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about ENZY :

    Quarterly/Annual Reports about ENZY:

      News about ENZY:

      Articles On GuruFocus.com
      What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

      More From Other Websites
      Enzymotec Ltd. to Report Second Quarter Fiscal Year 2014 Financial Results Jul 24 2014
      Enzymotec Ltd. to Report Second Quarter Fiscal Year 2014 Financial Results Jul 24 2014
      Enzymotec Ltd. Announces Publication of Clinical Study Results on Crying Reduction Following Usage... Jul 07 2014
      Enzymotec Ltd. Announces Publication of Clinical Study Results on Crying Reduction Following Usage... Jul 07 2014
      Enzymotec Ltd. Reports Commercial Introduction of Its Innovative Omega PC(TM) Advanced Fish Oil... Jun 23 2014
      Has Enzymotec Been Over-Punished? Jun 09 2014
      Enzymotec Ltd. to Present New Findings Regarding Positive Effects of INFAT(R) on Chinese Babies... Jun 05 2014
      Enzymotec Ltd. to Participate in the Jefferies 2014 Global Healthcare Conference May 23 2014
      Enzymotec Ltd. Announces an Extraordinary General Meeting of Shareholders to Approve Its... May 20 2014
      Enzymotec (ENZY) Crumbles: Stock Falls by 6.2% May 19 2014
      Enzymotec reports request for arbitration by AAK May 15 2014
      Enzymotec Reports a Request for Arbitration by AAK May 15 2014
      Enzymotec price target lowered to $26-$28 from $32-$34 at Wells Fargo May 15 2014
      Enzymotec's (ENZY) CEO Ariel Katz on Q1 2014 Results - Earnings Call Transcript May 14 2014
      Why Enzymotec (ENZY) Plunged to a One-Year Low Today May 14 2014
      Enzymotec sees FY14 EPS 64c-94c, consensus 86c May 14 2014
      Enzymotec reports Q1 EPS 24c, consensus 17c May 14 2014
      Enzymotec Ltd. Reports First Quarter 2014 Unaudited Financial Results May 14 2014
      Q1 2014 Enzymotec Ltd Earnings Release - Before Market Open May 14 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide